Print this page
-
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Protocol: 081602Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-Muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction.
Protocol: 081804Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Other Male Genital
Other Female Genital -
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE].
Protocol: 081910Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney